Table 1 SATB1-expression in relation to clinicopathological parameters and SATB2-expression

Age, years, M (IQR)

66 (61–72)

69 (64–74)

2

0.681

67 (62–72)

67 (57–70)

2

0.981

Sex, n (%)

0.469

0.777

Women

41 (48%)

8 (38%)

2

26 (55%)

8 (50%)

1

Men

44 (52%)

13 (62%)

21 (45%)

8 (50%)

1

Tumour origin, n (%)

0.852

0.487

Duodenum

12 (26%)

2 (13%)

Ampulla Intestinal type

35 (74%)

14 (87%)

2

Ampulla Pancreatobiliary type

16 (19%)

3 (14%)

Distal bile duct

34 (40%)

10 (48%)

1

Pancreas

35 (41%)

8 (38%)

1

Tumour size, mm, M (IQR)

30 (25–35)

28 (21–30)

2

0.799

25 (15–40)

30 (24–40)

2

0.848

Differentiation grade, n (%)

0.211

0.148

Well-moderate

34 (40%)

5 (24%)

1

26 (55%)

5 (31%)

1

Poor

51 (60%)

16 (76%)

1

21 (45%)

11 (69%)

1

T-stage, n (%)

1.000

0.860

T1

2 (2%)

0

1

4 (9%)

0

1

T2

8 (9%)

2 (10%)

8 (17%)

3 (19%)

1

T3

61 (72%)

16 (76%)

1

18 (38%)

7 (44%)

T4

14 (16%)

3 (14%)

17 (36%)

6 (37%)

N-stage, n (%)

0.421

0.564

N0

25 (29%)

4 (19%)

2

26 (55%)

7 (44%)

2

N1-N2

60 (71%)

17 (81%)

21 (45%)

9 (56%)

Margins, n (%)

1.000

1.000

R0

5 (6%)

1 (5%)

1

13 (28%)

4 (25%)

1

R1-Rx

80 (94%)

20 (95%)

1

34 (72%)

12 (75%)

1

Perineural growth, n (%)

0.232

0.533

No

20 (24%)

2 (10%)

1

34 (72%)

10 (62%)

1

Yes

65 (76%)

19 (90%)

1

13 (28%)

6 (38%)

1

Invasion of lymphatic vessels, n (%)

0.792

0.081

No

25 (29%)

7 (33%)

1

25 (53%)

4 (25%)

Yes

60 (71%)

14 (67%)

1

22 (47%)

12 (75%)

2

Invasion of blood vessels, n (%)

0.070

0.594

No

60 (71%)

10 (48%)

1

44 (94%)

14 (87%)

2

Yes

25 (29%)

11 (52%)

1

3 (6%)

2 (13%)

Growth in peripancreatic fat, n (%)

0.760

0.545

No

18 (21%)

3 (14%)

2

32 (68%)

9 (56%)

2

Yes

67 (79%)

18 (86%)

15 (32%)

7 (44%)

SATB2, n (%)

0.092

0.422

Negative

84 (99%)

18 (90%)

2

40 (89%)

13 (81%)

0

Positive

1 (1%)

2 (10%)

0

5 (11%)

3 (19%)

0

Missing

0

1

0

2

0

2

Adjuvant chemotherapy, n (%)

0.739

0.301

No adjuvant

41 (48%)

9 (43%)

1

35 (74%)

10 (63%)

2

5FU-analogue

5 (6%)

3 (14%)

4 (9%)

1 (6%)

Gemcitabine

35 (41%)

9 (43%)

5 (11%)

2 (13%)

Gemcitabine + capecitabine

1 (1%)

0

1

0

1 (6%)

Oxaliplatin +5-FU analogue

1 (1%)

0

3 (6%)

1 (6%)

Gemcitabine + oxaliplatin

2 (2%)

0

0

1 (6%)

Recurrence

0.250

0.658

No

16 (19%)

3 (14%)

1

27 (57%)

7 (44%)

1

Yes, local only

25 (29%)

3 (14%)

1

3 (6%)

1 (6%)

Yes, non-local

44 (52%)

15 (71%)

17 (36%)

8 (50%)

1

Included in survival analyses

1.000

1.000

Yes

84 (99%)

21 (100%)

0

45 (96%)

16 (100%)

0

No

1 (1%)

0

2

2 (4%)

0

2